RE:Douglas Loe in Septemer
Im not even sure the Adcomm panel was grasping the application for MCNA. There seemed to be an undercurrent of opposition from the start of the discussion. I'm not convinced that the risk/benefit question was the apex of the decision for many voters. I sensed a pre determined NO without truly weighing the intended question.
It matters not at this point but having a US pharma partner might have helped. Either way it will be ugly tomorrow.